Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 36

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 36
---
 chairs to report findings regarding material risk exposures to the Board as quickly as possible. The Board does not believe that its role in the oversight of our risks affects the Board’s leadership structure.

The Board is also committed to prioritizing environmental, social, and governance (“ESG”) issues. Our Board works closely with our management team to promote awareness of ESG issues and to integrate ESG promotion into our long-term business strategy.

MEETINGS OF THE BOARD OF DIRECTORS

Our Board met ten times during 2024. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served during the portion of 2024 for which he or she was a director or committee member.

In the fiscal year ending December 31, 2024, our independent directors (within the meaning of the applicable Nasdaq listing standards) met regularly in executive sessions at which only our independent directors were present.

<div align='center'>34</div>

Information Regarding Committees of the Board The Board has three committees: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. The following table provides current membership for each of the Board committees and the 2024 meeting information for each of the Board committees.

| Name                   |     | Audit |     | Compensation |     | Nominating and Corporate Governance |
| Thomas D. Anderson     |     |       |     |           X* |     |                                   X |
| John B. Bode           |     |     X |     |              |     |                                  X* |
| Douglas W. Calder      |     |       |     |            X |     |                                     |
| Wendy Dixon, Ph.D.     |     |     X |     |              |     |                                     |
| Tamara A. Favorito     |     |    X* |     |              |     |                                     |
| Neil F. McFarlane      |     |       |     |              |     |                                     |
| Alvin Shih, M.D.       |     |       |     |            X |     |                                   X |
| Corey Watton           |     |     X |     |            X |     |                                     |
| Total meetings in 2024 |     |     5 |     |            4 |     |                                   4 |

*Committee Chair

| BELOW IS A DESCRIPTION OF EACH COMMITTEE OF THE BOARD. |

Audit Committee The Audit Committee reviews our internal accounting procedures and consult